Current status of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus isolated from patients with skin and soft tissue infections in Japan

J Dermatol. 2020 Nov;47(11):1280-1286. doi: 10.1111/1346-8138.15506. Epub 2020 Jul 21.

Abstract

The USA300 clone, which produces Panton-Valentine leukocidin (PVL), is a major pathogenic community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) clone that causes intractable skin infections. Recently, PVL-positive CA-MRSA, including USA300 clones, have emerged in both communities and hospitals in Japan. To prevent an outbreak of PVL-positive MRSA, infected patients should be treated with effective antimicrobial agents at community clinics. Herein, we investigate molecular epidemiological characteristics of PVL-positive MRSA isolated from outpatients with skin and soft tissue infections (SSTI), which are common community-onset infectious diseases. The detection rate of MRSA was 24.9% (362 strains) out of 1455 S. aureus strains isolated between 2013 and 2017. Among the MRSA strains, 15.5% (56 strains) were PVL-positive strains and associated with deep-seated skin infections. Molecular epidemiological analyses of PVL-positive MRSA showed that USA300 was the predominant clone (53.6%, 30 strains) and was identified in Kanto (18 strains), Kagawa (nine strains), Tohoku (two strains) and Hokkaido (one strain). Notably, minocycline and fusidic acid were effective against all PVL-positive MRSA strains. Hence, our data reveals the current status of PVL-positive MRSA isolated from patients with SSTI in Japan. Continuous surveillance of CA-MRSA is necessary to monitor latest prevalence rates and identify effective antimicrobial agents for PVL-positive MRSA strains.

Keywords: Panton-Valentine leukocidin; USA300 clone; antimicrobial susceptibility; community-acquired methicillin-resistant Staphylococcus aureus; skin and soft tissue infection.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Toxins
  • Community-Acquired Infections* / drug therapy
  • Community-Acquired Infections* / epidemiology
  • Exotoxins / genetics
  • Humans
  • Japan / epidemiology
  • Leukocidins / genetics
  • Methicillin-Resistant Staphylococcus aureus* / genetics
  • Soft Tissue Infections* / drug therapy
  • Soft Tissue Infections* / epidemiology
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / epidemiology
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents
  • Bacterial Toxins
  • Exotoxins
  • Leukocidins
  • Panton-Valentine leukocidin